Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06869551 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

A Phase 3 study of Juvenile Psoriatic Arthritis, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 3
Development phase
60
Enrollment target
20
Study locations

NCT06869551 is a Phase 3 study of Juvenile Psoriatic Arthritis that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06869551, a Phase 3 study of Juvenile Psoriatic Arthritis, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 3
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Conditions Studied

Juvenile Psoriatic Arthritis

Interventions

  • OTHER Placebo
  • DRUG Deucravacitinib

Study Locations (20)

Rio Grande do Sul

  • Local Institution - 0033 - Porto Alegre
  • LMK Serviços Médicos S/S - Porto Alegre
  • Local Institution - 0069 - Xangri-lá

Other

  • Local Institution - 0027 - Rio de Janeiro
  • Local Institution - 0047 - São Paulo
  • Local Institution - 0010 - São Paulo

Ohio

  • Local Institution - 0065 - Cincinnati
  • Local Institution - 0066 - Cleveland

Paraná

  • Local Institution - 0013 - Curitiba
  • Local Institution - 0072 - Curitiba

California

  • Local Institution - 0038 - Lancaster

Illinois

  • Local Institution - 0020 - Chicago

Indiana

  • Local Institution - 0023 - Indianapolis

New York

  • Local Institution - 0059 - North New Hyde Park

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-03-13
Est. Completion 2031-03-04
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06869551

The ClinicalTrials.gov registry entry for NCT06869551 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Juvenile Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06869551 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Rio Grande do Sul, Other, Ohio.

Frequently Asked Questions

What is clinical trial NCT06869551 about?

NCT06869551 is a clinical study titled "A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis". The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

What is the current status of trial NCT06869551?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-03-13. Estimated completion is 2031-03-04.

What conditions does trial NCT06869551 study?

This clinical trial studies the following conditions: Juvenile Psoriatic Arthritis.

What interventions are being tested in trial NCT06869551?

The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).

Who is sponsoring clinical trial NCT06869551?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06869551 being conducted?

This trial has 20 study locations across California, Illinois, Indiana, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Juvenile Psoriatic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Juvenile Psoriatic Arthritis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.